NCT06947083View on ClinicalTrials.gov

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

April 30, 2029

Study Completion Date

April 30, 2029

Conditions
Myeloma
Interventions
DRUG

Elranatamab

Maintenance therapy

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT06947083 - Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma | Biotech Hunter | Biotech Hunter